Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isolated mucinous adrenal metastasis in a breast cancer patient.
Demirci U, Buyukberber S, Cakir T, Poyraz A, Baykara M, Karakus E, Tufan G, Benekli M, Coskun U. Demirci U, et al. Among authors: coskun u. J Oncol Pharm Pract. 2011 Dec;17(4):444-7. doi: 10.1177/1078155210384893. Epub 2011 Jan 31. J Oncol Pharm Pract. 2011. PMID: 21282299
Synchronous bilateral breast cancer in a patient with kindler syndrome.
Tonyali O, Tufan G, Benekli M, Coskun U, Buyukberber S. Tonyali O, et al. Among authors: coskun u. Clin Breast Cancer. 2012 Apr;12(2):145-6. doi: 10.1016/j.clbc.2011.09.003. Epub 2011 Nov 4. Clin Breast Cancer. 2012. PMID: 22054710 No abstract available.
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Yildiz R, et al. Among authors: coskun u. J Cancer Res Clin Oncol. 2012 Nov;138(11):1845-52. doi: 10.1007/s00432-012-1264-5. Epub 2012 Jun 22. J Cancer Res Clin Oncol. 2012. PMID: 22722713
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, Ozdemir NY, Yazilitas D, Benekli M, Uner A, Yamac D, Demirci U, Yildiz R, Karaca H, Unal OU, Bal O, Gumus M, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: coskun u. J Cancer Res Clin Oncol. 2012 Dec;138(12):2145-51. doi: 10.1007/s00432-012-1296-x. Epub 2012 Aug 10. J Cancer Res Clin Oncol. 2012. PMID: 22878681
Clinicopathological features in bilateral breast cancer.
Baykara M, Ozturk SC, Buyukberber S, Helvaci K, Ozdemir N, Alkis N, Berk V, Koca D, Coskun U, Oksuzoglu B, Uncu D, Arpaci E, Ustaalioglu BO, Demirci U, Kucukoner M, Dogu GG, Alici S, Akman T, Ozkan M, Aslan UY, Durnali AG, Benekli M. Baykara M, et al. Among authors: coskun u. Asian Pac J Cancer Prev. 2012;13(9):4571-5. doi: 10.7314/apjcp.2012.13.9.4571. Asian Pac J Cancer Prev. 2012. PMID: 23167382 Free article.
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Tonyali O, Benekli M, Berk V, Coskun U, Ozkan M, Yildiz R, Ucgul E, Sevinc A, Uncu D, Demirci U, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: coskun u. J Cancer Res Clin Oncol. 2013 Jun;139(6):981-6. doi: 10.1007/s00432-013-1409-1. Epub 2013 Mar 5. J Cancer Res Clin Oncol. 2013. PMID: 23463098 Clinical Trial.
Management of brain metastases from non-small cell lung cancer.
Baykara M, Kurt G, Buyukberber S, Demirci U, Ceviker N, Algin E, Coskun U, Aykol S, Emmez H, Ozet A, Benekli M. Baykara M, et al. Among authors: coskun u. J Cancer Res Ther. 2014 Oct-Dec;10(4):915-21. doi: 10.4103/0973-1482.137939. J Cancer Res Ther. 2014. PMID: 25579528 Free article.
298 results